Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eos Energy Enterprises Inc (EOSE) vs Eli Lilly And Co (LLY) Price & Performance

Eos Energy Enterprises IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Eos Energy Enterprises Inc vs Eli Lilly And Co — how do they compare? Eos Energy Enterprises Inc trades at $4.27 (market cap $1.47B), while Eli Lilly And Co trades at $1,214.23 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 748.3× Eos Energy Enterprises Inc's market cap, and Eli Lilly And Co pays a 0.56% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.

EOSELLY
Market Cap
$1.47B$1.10T
Sector
EnergyHealth
52-Week High
$19.19$1.24K
52-Week Low
$3.14$639.43
Enterprise Value
$1.81B$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eos Energy Enterprises Inc

Eos Energy Enterprises (EOSE) trades at $4.15, up 5.33% today, but faces significant financial challenges with a net income margin of -246.76% and negative cash flow from operations. The company reported record Q2 2026 revenue but missed earnings expectations with a $1.20 per share loss. Technical indicators show a mixed picture with bullish overall signals but bearish moving averages, while analyst sentiment remains cautious with 70% hold ratings.

Despite revenue growth potential in the energy storage market, EOSE carries substantial risk due to persistent losses, high debt-to-asset ratio of 91.87%, and ongoing shareholder litigation. The consensus price target of $7.75 suggests upside potential, but investors should weigh the company's financial instability against its growth prospects in the competitive battery storage sector.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eos Energy Enterprises Inc

Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.

Read more on EOSE

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY